Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HB 0030

Next Previous
Drug Profile

HB 0030

Alternative Names: HB-0030; Recombinant Humanized Anti-TIGIT Monoclonal Antibody - Huabo Biopharm

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Huabo Biopharm; Huaota Biopharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (IV, Injection)
  • 02 Jun 2023 Efficacy and adverse events data from a phase I trial in Solid tumour presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 21 Dec 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (IV) (NCT05706207)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top